tbuckley/cabot-search huggingface dataset:
G15 : The association of sofosbuvir and daclatasvir for treating severe recurrence of HCV infection after liver transplantation: Results from a large french prospective multicentric ANRS CO23 CUPILT cohort
Authors: A. Coilly, C. Fougerou, V. De Ledinghen, P. Houssel-Debry, C. Duvoux, V. Di Martino, S. Radenne, N. Kamar, L. D’Alteroche, V. Leroy, V. Canva, P. Lebray, C. Moreno, J. Dumortier, C. Silvain, C. Besch, P. Perre, D. Botta-Fridlund, R. Anty, A. Rohel, A. Renault, H. Danjou, J.-C. Duclos-Vallee, G.-P. Pageaux
Journal: Journal of Hepatology (2015)
Clinical performance of FXG(tm): RESP (Asp+) assay for aspergillus on respiratory specimens
Authors: C Lass-Florl, J Bille, D.S. Perlin, S Park, Katrien Lagrou, E Harrison, Wouter Meersseman, X Cui, M Hughes, D.W. Denning
Journal: Clinical Microbiology and Infection (2008)
Targeting Metabolic Pathways for Leukemia Treatment
Authors: Simone Mirabilii, Maria Rosaria Ricciardi, Matteo Allegretti, Roberto Licchetta, Stefano Iacovelli, Paola Bergamo, Maria Teresa Petrucci, Raffaella Nicolai, Gianfranco Peluso, Robin Foà, Giuliana Alimena, Agostino Tafuri
Journal: Blood (2012)
Preferential association of hepatitis C virus with CD19+ B cells is mediated by complement system
Authors: Richard Y. Wang, Patricia Bare, Valeria De Giorgi, Kentaro Matsuura, Kazi Abdus Salam, Teresa Grandinetti, Cathy Schechterly, Harvey J. Alter
Journal: Hepatology (2016)

Extrahepatic disease manifestations are common in chronic hepatitis C virus (HCV) infection. The mechanism of HCV‐related lymphoproliferative disorders is not fully understood. Recent studies have found that HCV in peripheral blood mononuclear cells from chronically infected patients is mainly associated with cluster of differentiation 19‐positive (CD19 + ) B cells. To further elucidate this preferential association of HCV with B cells, we used in vitro cultured virus and uninfected peripheral blood mononuclear cells from healthy blood donors to investigate the necessary serum components that activate the binding of HCV to B cells. First, we found that the active serum components were present not only in HCV carriers but also in HCV recovered patients and HCV‐negative, healthy blood donors and that the serum components were heat‐labile. Second, the preferential binding activity of HCV to B cells could be blocked by anti‐complement C3 antibodies. In experiments with complement‐depleted serum and purified complement proteins, we demonstrated that complement proteins C1, C2, and C3 were required to activate such binding activity. Complement protein C4 was partially involved in this process. Third, using antibodies against cell surface markers, we showed that the binding complex mainly involved CD21 (complement receptor 2), CD19, CD20, and CD81; CD35 (complement receptor 1) was involved but had lower binding activity. Fourth, both anti‐CD21 and anti‐CD35 antibodies could block the binding of patient‐derived HCV to B cells. Fifth, complement also mediated HCV binding to Raji cells, a cultured B‐cell line derived from Burkitt's lymphoma. Conclusion : In chronic HCV infection, the preferential association of HCV with B cells is mediated by the complement system, mainly through complement receptor 2 (CD21), in conjunction with the CD19 and CD81 complex. (H epatology 2016;64:1900‐1910).
Quantitative Flow Cytometric Assessment of CD36 (Platelet Glycoprotein IV) Expression on Monocytes and Platelets: Assay Development, Role in Plasmodium falciparum Risk Assessment, and Relationship to Sickle Hemoglobin.
Authors: Christine M. Cserti, Songyi Xu, Robert Sutherland, Rakesh Nayar, Marciano Reis, Michelle E. Dorn, Robert O. Quagliaroli, John D. Sullivan, Frederic I. Preffer, Walter H. Dzik
Journal: Blood (2007)
Ombitasvir (ABT 267), Ritanavir Boost with Dastasbuvir (ABT 333) and Prataspravir (ABT 450) with or without Ribavirin (RBV) in G1 Special Population in Hemodialysis (HD) in Chronic Hepatitixs C (HCV) Patients Drop C Trial
Authors: P.P. Basu, N.J. Shah, M. Aloysius, L. Kavali, E. Shehi
Journal: Journal of Hepatology (2016)
Phase 1/1b Study of RG7388, a Potent MDM2 Antagonist, in Acute Myelogenous Leukemia (AML) Patients (Pts)
Authors: Karen Yee, Giovanni Martinelli, Norbert Vey, Michael J. Dickinson, Karen Seiter, Sarit Assouline, Mark Drummond, Sung-Soo Yoon, Margaret Kasner, Je-Hwan Lee, Kevin R. Kelly, Steven Blotner, Brian Higgins, Steven Middleton, Gwen Nichols, Gong Chen, Hua Zhong, William E. Pierceall, Jianguo Zhi, Lin-Chi Chen
Journal: Blood (2014)
Large Solitary Hepatocellular Carcinomas Treated with Transarterial Chemoembolization: In Which BCLC Stage Patients Should Be Allocated?
Authors: B.C. Odisio, T.A. Figueira, M.E. Abdelsalam, S. Sabir, S. Sabir, A. Mahvash, M.J. Wallace, J.-N. Vauthey, A.O. Kaseb
Journal: Journal of Hepatology (2016)
Autoimmune Hepatitis is Associated with Stable Immunization against Intestinal Commensal Bacteria
Authors: F. Goeser, B. Krämer, P. Lutz, D. Kaczmarek, C. Finnemann, S. Fazeli, M. Parcina, C.P. Strassburg, A. Hörauf, I. Bekeredjian-Ding, J. Nattermann, U. Spengler
Journal: Journal of Hepatology (2016)
HBV E Antigen and its Precursors Promote the Progress of HCC by Interacting with Numb and Decreasing P53 Activity
Authors: D. Liu, L. Cui, Y. Wang, G. Yang, J. He, R. Hao, C. Fan, M. Qu, Z. Liu, M. Wang, L. Chen, D. Guo
Journal: Journal of Hepatology (2016)
High Efficacy of Abt-493 and Abt-530 in Hcv Genotype 1 Infected Patients who Have Failed Direct-Acting Antiviral-Containing Regimens: The Magellan-I Study
Authors: F. Poordad, S.C. Gordon, A. Asatryan, F. Felizarta, R.W. Reindollar, C. Landis, M.W. Fried, D.E. Bernstein, T.I. Ng, C.-W. Lin, R. Liu, J. Kort, F.J. Mensa
Journal: Journal of Hepatology (2016)
Gadoxetic Acid Disodium-Enhanced MRI Combined Surveillance Improves Clinical Outcome by Sensitive Detection of Early Stage Hepatocellular Carcinoma, Compared with Ultrasonography Based Surveillance, in Patients with Cirrhosis
Authors: S.J. Yu, J.-J. Yoo, Y.Y. Cho, W.-M. Choi, M. Lee, D.H. Lee, Y. Cho, E.-J. Cho, J.-H. Lee, Y.J. Kim, J.M. Lee, C.Y. Kim, J.-H. Yoon
Journal: Journal of Hepatology (2016)
High Resolution Analysis for Genotypes and Subgenotypes Identification in Hepatitis C Reveals the Importance of Mixed Infections for Optimal Therapy
Authors: J.A. Del Campo, M. Parra, S. Delgado, M. García-Valdecasas, J. Gregori, J. Quer, S. Bernal, J.C. Palomares, L. Grande, M. Romero-Gómez
Journal: Journal of Hepatology (2016)
Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir + Ribavirin (3D + RBV) Treatment of Hepatitis C (HCV) Genotype 1 (GT1) Infected Patients (pts) after Failure to Previous First Generation Protease-Inhibitor (PI) Therapy Interim Analysis
Authors: B. Hunyady, M. Abonyi, J. Gervain, G. Horváth, Z. Gerlei, G. Lengyel, E. Makkai, Z. Péter, M. Pusztay, P. Ribiczey, L. Rókusz, C. Sarrazin, F. Schneider, M. Schneider, F. Szalay, I. Tornai, A. Tusnádi, E. Újhelyi, M. Makara
Journal: Journal of Hepatology (2016)
Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The “Peg-Be-Yond” Study
Authors: L. Wei, V. Pavlovic, A.T. Bansal, X.-P. Chen, G.R. Foster, H. He, J.-H. Kao, P. Lampertico, Y.-F. Liaw, A. Motoc, G. Papatheodoridis, T. Piratvisuth, R. Plesniak, C. Wat
Journal: Journal of Hepatology (2016)
Post-Transplantation High Dose Cyclophosphamide As Gvhd Prophylaxis in 9/10 HLA-Matched Unrelated Donors Hematopoietic Stem Cell Transplantation
Authors: Rohtesh S. Mehta, Rima M Saliba, Julianne Chen, Gabriela Rondon, Aimee E Hammerstrom, Amin M. Alousi, Muzaffar H. Qazilbash, Qaiser Bashir, Sairah Ahmed, Uday R. Popat, Chitra M. Hosing, Issa F. Khouri, Elizabeth J. Shpall, Richard E. Champlin, Stefan O. Ciurea
Journal: Blood (2015)
The Bile Acid Tauroursodeoxycholic Acid Cooperates with N-Acetylcysteine in the Treatment of Experimental Acetaminophen-Induced Hepatotoxicity
Authors: A. Paridaens, L. Devisscher, S. Raevens, E. Bogaerts, Y.-P. Vandewynckel, X. Verhelst, I. Mannaerts, L. Van Grunsven, H. Van Vlierberghe, I. Colle, A. Geerts
Journal: Journal of Hepatology (2016)
Presenting Features and Outcome of Elderly Chronic Lymphocytic Leukemia Patients Diagnosed at the Age of 80 Years or Above. An ICLLSG Study.
Authors: Osnat Bairey, Rosa Ruchlemer, Naomi Rahimi-Levene, Yair Herishanu, Andrei Braester, Abraham Klepfish, Lev Shvidel
Journal: Blood (2010)
Olfactomedin 4, An Indicator of the Existence of Neutrophil Subsets.
Authors: Stine Novrup Clemmensen, Sara Roervig, Jonathan Wren, Martin Illemann, Andreas Glenthoj, Helena Mora-Jensen, Elisabeth Cramer, Maria Torp Larsen, Lars C. Jacobsen, Jack B Cowland, Niels Borregaard
Journal: Blood (2010)
Practice Gaps and Barriers To Optimal Care Among Hematologists and Medical Oncologists Treating Patients With Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), and B-Cell Lymphomas In The United States: Results Of a Two-Phase Qualitative/Quantitative Study
Authors: Kevin L. Obholz, Patrice Lazure, Andrew Bowser, Sophie Péloquin, Sean M. Hayes, Jim Mortimer, Eric D. Peterson, B. Douglas Smith
Journal: Blood (2013)
Genome-Wide Association Study (Gwas) of Liver Fibrosis Phenotypes in Patients with Primary Sclerosing Cholangitis (Psc) Reveals Common Genetic Variation Influencing Serum Levels of Lysyl Oxidase-Like-2 (Loxl2)
Authors: P.R. Shea, B. Eksteen, G.M. Hirschfield, M.L. Shiftman, H.L.A. Janssen, A.J. Montano-Loza, Z. Goodman, S.E. Kleinstein, R.P. Myers, G.M. Subramanian, J.G. McHutchison, C.L. Bowlus, M. Manns, R. Chapman, C. Levy, A.J. Muir, D.B. Goldstein
Journal: Journal of Hepatology (2016)
Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)
Authors: Raphael Szalat, Matija Dreze, Mehmet Kemal Samur, Anne S. Calkins, Giovanni Parmigiani, Herve Avet-Loiseau, Kenneth C. Anderson, Jean-Paul Fermand, Jean-Bernard Lazaro, Nikhil C. Munshi
Journal: Blood (2014)
New Recommendations of Baveno Vi Conference for the Screening of Portal Hypertension: An Independent Sequential Validation in Patients with Compensated Viral Cirrhosis Taking into Account Virological Status (Anrs Co12 Cirvir Cohort)
Authors: D. Thabut, C. Bureau, R. Layese, V. Bourcier, L. Corvy, V. Petrov-Sanchez, P. Marcellin, D. Guyader, S. Pol, D. Larrey, F. Zoulim, D. Roulot, V. De Ledinghen, D. Ouzan, A. Tran, J.-P. Bronowicki, G. Riachi, P. Cales, J.-M. Peron, L. Alric, M. Bourliere, P. Mathurin, J.-P. Zarski, P. Roudot-Thorava, P. Nahon
Journal: Journal of Hepatology (2016)
“Real Life” Safety and Efficacy of IFN/RBV-Free, Full-Dose SOF-Based Therapy in Kidney Transplanted Patients
Authors: A. Moreno, A. Fernandez, M.J. Vivancos, M.J. Pérez-Elías, C. Quereda, S. Elías, F. Liaño, M. García-González, J. Graus, S. del Campo, A.D. de Santiago, M.L. Mateos, R. Bárcena, S. Moreno
Journal: Journal of Hepatology (2016)
Coronary Artery Calcium Score and Framingham Score in Evaluation of Cardiovascular Risk after Liver Transplantation
Authors: L. Carone, C.P. Oliveira, M.R. Alvares-da-Silva, J.T. Stefano, D.R.B. Terrabuio, E. Abdala, F.J. Carrilho, A.Q. Farias, L.A.C. D’Albuquerque
Journal: Journal of Hepatology (2016)
A phase II trial of azacitidine (NSC-102816) and gemtuzumab ozogamicin (NSC-720568) as induction and post-remission therapy in patients of age 60 and older with previously untreated non-M3 acute myeloid leukemia: SWOG S0703 protocol—Report on the good-risk patients.
Authors: Sucha Nand, Holly Gundacker, John E. Godwin, Cheryl L. Willman, Thomas Norwood, Harry Paul Erba, Dianna S. Howard, Steven E. Coutre, Megan Othus, Frederick R. Appelbaum
Journal: Journal of Clinical Oncology (2012)

6502 Background: In pts with AML, response rates to standard chemotherapy decrease and early death rates increase with age. Whereas pts &lt; 56 yrs of age have a complete remission (CR) rate of 65% and 30 day mortality risk of &lt;3%, the respective figures are 33% and 31% in pts &gt; 75 yrs. This trial was designed to improve safety and efficacy by using agents with low toxicity, different mechanisms of action and possible synergy. The treatment could be given in the outpatient setting. Methods: Newly diagnosed pts with non-M3 AML, 60 yrs or older, were treated as follows: Induction: Hydroxyurea 1500 mg b.i.d till WBC &lt;10,000/mcL, followed by azacitidine 75 mg/m2/day s/cu or iv days 1-7, gemtuzumab ozogamicin (GO) 3mg/m2 on D8. Induction treatment was repeated for residual disease on D14. Pts achieving CR received a consolidation treatment identical to the induction treatment. This was followed by 4 cycles of azacitidine 75/m2/day, D1-7, given q 4 weeks. Subsequent therapy was optional. Promoter and global methylation studies were performed at defined time points. Results: Pts were stratified into good risk (age 60-69 or Zubrod 0-1) and poor risk (age ≥70 and Zubrod 2 or 3) groups. The results presented here are from the good risk cohort. Eighty-three pts were entered of whom 79 are evaluable. Median age was 71 yrs (60-88) and 49 were males. Thirty-five achieved CR/CRi (44%: 95% CI 33%-56%). Median overall survival was 11 months and median relapse-free survival with patients achieving a CR/CRi was 8 months. Six patients (8%), 3 with disease progression, died within 30 days of registration. The main non-hematologic toxicity was neutropenic fever (Grade 3 or higher), seen in 27 patients. Conclusions: The combination of hydroxyurea, azacitidine and GO is associated with a low induction mortality, can be given in the outpatient setting and produces results which compare favorably with standard chemotherapy regimens in elderly patients with AML. Our results are sufficiently encouraging to warrant further studies of this approach. Clinical Trials.govIdentifier: NCT00658814.
Kinomics Profiling Of Pediatric Acute Myeloid Leukemia Based On Prognosis
Authors: Hasan Mahmud, Arja ter Elst, Frank J. G. Scherpen, T G J Meeuwsen-de Boer, Kim R. Kampen, Victor Guryev, Valerie de Haas, Steven M. Kornblau, Eveline S. J. M. de Bont
Journal: Blood (2013)
TLR-10 Single Nucleotide Polymorphism is Associated to Poor Short Term Survival in Cirrhotic Patients with Acute on Chronic Liver Failure Precipitated by Bacterial Infections
Authors: P. Caraceni, M. Domenicali, M. Baldassarre, F.A. Giannone, E. Marasco, M. Pavesi, V. Mantovani, P. Angeli, A. Gerbes, R. Moreau, R. Jalan, P. Ginès, V. Arroyo, M. Bernardi
Journal: Journal of Hepatology (2016)
High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies
Authors: E.J. Gane, S. Pianko, S.K. Roberts, A.J. Thompson, S. Zeuzem, E. Zuckerman, Z.B. Ari, G.R. Foster, K. Agarwal, A.L. Laursen, J. Gerstoft, W. Gao, H.-C. Huang, B. Fitzgerald, J.J. Li, S. Wan, F. Dutko, B.-Y.T. Nguyen, J. Wahl, E. Barr, J.R. Butterton, R. Esteban
Journal: Journal of Hepatology (2016)
MER Tyrosine Kinase Positive Tumour Associated Macrophages Are a Novel Therapeutic Target in Hepatocellular Carcinoma
Authors: S.K. Mukherjee, O.T. Pop, E. Triantafyllou, W. Khamri, C. Bernsmeier, K.-K. Li, A. Suddle, C. Weston, S. Curbishley, M. Thursz, D. Adams, N. Heaton, A. Quaglia, C.G. Antoniades
Journal: Journal of Hepatology (2016)
The Effect of Sustained Virologic Response on Cerebral Metabolism and Neurocognition in Patients with Chronic Genotype 1 HCV Infection
Authors: M.P. Curry, N.P. Moczynski, L. Liu, L. Stamm, C. Yun, D.M. Brainard, J.G. McHutchison, D. Alsop, N.H. Afdhal
Journal: Journal of Hepatology (2016)
Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer
Authors: Mark D. Tyson, Amy J. Graves, Brock O’Neil, Daniel A. Barocas, Sam S. Chang, David F. Penson, Matthew J. Resnick
Journal: JAMA Surgery (2016)

The reporting of individual urologist rates of observation for localized prostate cancer may be a valuable performance measure with important downstream implications for patient and payer stakeholder groups. However, few studies have examined the urologist-level variation in the use of observation across all risk strata of prostate cancer.To measure variation in the use of observation at the urologist level by disease risk strata and to evaluate the association between the urologist-level rates of observation for men with low-risk and high-risk prostate cancer.With the use of linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data, a population-based study of men diagnosed with prostate cancer from January 1, 2004, to December 31, 2009, was performed in SEER catchment areas of the United States. A total of 57 639 men with prostate cancer with 1884 diagnosing urologists were identified. Data were analyzed from October 1 to December 31, 2015.The main outcome was observation, which is defined as the absence of definitive treatment within 1 year of diagnosis. In each risk stratum, a multivariable mixed-effects model was fit to characterize associations between observation and selected patient characteristics. From these models, the estimated probability of observation was calculated for each urologist within each risk stratum, and the association between the physician-level estimated rates of observation for low-risk and high-risk disease was assessed.Among the 57 639 men included in the study, the estimated probability of observation for low-risk disease varied impressively (mean, 27.8%; range, 5.1%-71.2%) at the individual urologist level. Considerably less urologist-level variation was seen in the use of observation for intermediate-risk disease (11.1%; range, 4.8%-31.5%) and high-risk disease (5.8%; range, 3.2%-16.5%). Furthermore, the estimated rates of observation for low- and high-risk disease were correlated at the urologist level (Spearman ρ = 0.17; P < .001). A comparable correlation was likewise observed among urologists with high-volume prostate cancer practices (Spearman ρ = 0.24; P < .001).Considerable urologist-level variation is seen in the use of observation for men with low-risk prostate cancer. More important, the use of observation for low-risk and high-risk patients with prostate cancer is correlated at the urologist level. This study reveals the strikingly variable use of observation among US urologists and establishes a framework for the use of urologist-level treatment signatures as a quality measure in the emerging value-based health care environment.
Infliximab biosimilars are safe, effective, and cheap, UK audit shows
Authors: Caroline White
Journal: BMJ (2016)

Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (marketed as Remicade)—are safe and effective and could halve the cost of inflammatory bowel disease (IBD) treatment, a report by the Royal College of Physicians has found.1

Use of these drugs could cut the cost of an annual course of treatment from around £10 000 (€11 700: $13 000) to around £5000, the authors said.

Given their reduced cost, clinicians should use biosimilars as first line treatment for appropriate patients with active IBD and should consider switching those currently being treated with Remicade, said the report.

Only a fifth of patients were receiving infliximab biosimilars (Inflectra and Remsima), the audit found, prompting the authors to …
Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease
Authors: Muntasir Mamun Majumder, Raija Silvennoinen, Pekka Anttila, David Tamborero, Samuli Eldfors, Juha Lievonen, Riikka J Karjalainen, Heikki Kuusanmäki, Alun Parsons, Minna Suvela, Kimmo Porkka, Caroline Heckman
Journal: Blood (2015)
Does Alcohol Dependency Explain Differences in Rates of Decompensated Cirrhosis among People with a Hepatitis C Notification? An International Comparison
Authors: M. Alavi, N. Janjua, A. Yu, J. Grebely, E. Aspinall, H. Innes, H. Valerio, P. Hayes, M. Krajden, J. Amin, M. Law, J. George, D. Goldberg, S. Hutchinson, G. Dore
Journal: Journal of Hepatology (2016)
Melatonin’s Effect on the Secondary Biliary Cirrhosis Induced by Ligation of Biliary Duct
Authors: N.A.P. Marroni, J.R. Colares, E.G. Schemitt, R.M. Hartmann, F. Licks, M. Do Couto Soares, A. DalBosco
Journal: Journal of Hepatology (2016)
Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline
Authors: Elizabeth C. Ballinger, Mala Ananth, David A. Talmage, Lorna W. Role
Journal: Neuron (2016)

Recent work continues to place cholinergic circuits at center stage for normal executive and mnemonic functioning and provides compelling evidence that the loss of cholinergic signaling and cognitive decline are inextricably linked. This Review focuses on the last few years of studies on the mechanisms by which cholinergic signaling contributes to circuit activity related to cognition. We attempt to identify areas of controversy, as well as consensus, on what is and is not yet known about how cholinergic signaling in the CNS contributes to normal cognitive processes. In addition, we delineate the findings from recent work on the extent to which dysfunction of cholinergic circuits contributes to cognitive decline associated with neurodegenerative disorders.
High mRNA expression of LMO4, a BRCA1 downregulator, correlates with better prognosis in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.
Authors: Santiago Viteri Ramirez, Carlota Costa, Ana Gimenez Capitan, Susana Benlloch, Miquel Taron, Jose Javier Sanchez, Amaya Gasco, Alejandro Martinez-Bueno, Niki Karachaliou, Carlos Camps, Teresa Moran, Enric Carcereny Costa, Bartomeu Massuti, Felipe Cardenal, Rut Porta, Joaquim Bosch, Ramon Palmero, Cristina Buges, Rafael Rosell
Journal: Journal of Clinical Oncology (2012)

e18137 Background: Advanced NSCLC p with EGFR activating mutations show an impressive progression-free survival (PFS) to erlotinib. The co-existence of the EGFR T790M mutation, in conjunction with high BRCA1 mRNA levels, affected PFS to erlotinib (Rosell et al. CCR 2011). LMO4 is a negative regulator of BRCA1 function in sporadic breast cancers, and CtIP can bind to BRCA1 and LMO4. We have assessed the expression of CtIP, LMO4 and BRCA1 and examined the impact of CtIP and LMO4 levels on outcome. Methods: mRNA expression of LMO4 and CtIP was examined by RT-PCR in the original pretreatment tumor biopsies of 81 NSCLC p with sensitive EGFR mutations. Results: Expression of BRCA1 and LMO4 was successfully assessed in 55 p: median age, 68; 61.8% female; 98.2% Caucasian; 63.6% never-smokers; 81.8% ECOG PS &lt;2; 80% adenocarcinoma; 14.5% BAC; 4.5% LCC; 94.5% stage IV; 63.6% exon 19 deletion; 36.4% L858R mutation; 36.4% T790M; 83.1% showed clinical benefit to erlotinib (CR/PR/SD). BRCA1 expression was correlated with that of CtIP (r=0.31; P=0.01) and LMO4 (r=0.32; P=0.02). There was no correlation between CtIP and LMO4 (r=0.09; P=0.49). PFS for p with high LMO4 levels was not reached while it was 13 months (m) for p with low levels (P=0.006). Overall survival (OS) was not reached for p with high levels of LMO4 and was 31 m for p with low levels (P=0.17). No differences in PFS or OS were observed according to CtIP levels. When BRCA1 and LMO4 expression was analyzed together, PFS was not reached for p with low BRCA1 and high LMO4 levels and was 19 m for p with low levels of both genes (P=0.04). PFS was 8 m for p with high BRCA1 and low LMO4 levels and 18 m for p with high levels of both genes (P=0.03). In the multivariate analysis, BRCA1 and LMO4 expression emerged as markers of PFS (Table). Conclusions: BRCA1 and LMO4 mRNA expression can predict PFS to erlotinib in p with EGFR mutations and could be useful in the development of new therapeutic strategies. [Table: see text]
Socio-demographic influences on language structure and change: Not all learners are the same
Authors: Till Bergmann, Rick Dale, Gary Lupyan
Journal: Behavioral and Brain Sciences (2016)

The Now-or-Never bottleneck has important consequence for understanding why languages have the structures they do. However, not addressed by C&C is that the bottleneck may interact with who is doing the learning: While some languages are mostly learned by infants, others have a large share of adult learners. We argue that such socio-demographic differences extend and qualify C&C's thesis.